Dr Jeffrey Weinberg speaks to ecancer at ASCO 2026 about results from a phase 3 trial comparing resection and post-operative stereotactic radiation versus resection and cesium-131 tile-based radiation for treatment of newly diagnosed brain metastases.

He reports that the chances that brain metastases would grow back at the surgery site (surgical bed recurrence or SBR) were significantly improved with the tile-based radiation. This was also the case for surgical bed recurrence-free survival.

Dr Weinberg also highlights the 'fascinating' overall survival benefit, which would not normally be expected in a local control trial.

Read the news story here.